董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Vickie Capps | 女 | Director | 63 | 未披露 | 未持股 | 2025-09-18 |
| Winston Kung | 男 | Director | 49 | 未披露 | 未持股 | 2025-09-18 |
| David Campbell | -- | President and Chief Executive Officer, Director | 66 | 未披露 | 未持股 | 2025-09-18 |
| Jake Simson | 男 | Director | 39 | 未披露 | 未持股 | 2025-09-18 |
| Eric Dobmeier | 男 | Director | 56 | 未披露 | 未持股 | 2025-09-18 |
| Ron Barrett | -- | Director | 69 | 未披露 | 未持股 | 2025-09-18 |
| Natasha Hernday | 女 | Director | 53 | 未披露 | 未持股 | 2025-09-18 |
| Alana McNulty | 女 | Director | 62 | 未披露 | 未持股 | 2025-09-18 |
| Sheila Gujrathi | 女 | Director | 54 | 未披露 | 未持股 | 2025-09-18 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| David Campbell | -- | President and Chief Executive Officer, Director | 66 | 未披露 | 未持股 | 2025-09-18 |
| Andy Meyer | 男 | Chief Business Officer | 41 | 未披露 | 未持股 | 2025-09-18 |
| Thomas DiRaimondo | 男 | Chief Scientific Officer | 39 | 未披露 | 未持股 | 2025-09-18 |
| Zachariah McIver | 男 | Chief Medical Officer | 55 | 未披露 | 未持股 | 2025-09-18 |
| Charles Winter | 男 | Chief Technical Officer | 56 | 未披露 | 未持股 | 2025-09-18 |
董事简历
中英对照 | 中文 | 英文- Vickie Capps
-
Vickie Capps自2021年3月起担任Janux Therapeutics, Inc.的董事会成员。Vickie Capps从2002年7月到2013年12月，担任DJO Global, Inc.的全球首席财务官。2002年她加入DJO Global, Inc.。加入DJO Global, Inc.之前，她担任其他公共和私人公司的首席财务官。在她的职业生涯的早期，她担任Ernst & Young LLP的高级审计和会计专业人才。她目前担任Consonance Capital Partners（医疗投资公司）的高级顾问委员会的成员并且是 RF Surgical Systems, Inc.的董事会成员以及其审计委员会主席。从2007年到2010年7月被C. R. Bard, Inc.收购之前，她担任SenoRx, Inc.的董事会的成员。她是加州注册会计师并且是被the San Diego Business Journal认证的2009年和2010年年度首席财务官。她获得San Diego State University的工商管理会计学士学位。
Vickie Capps,has served as a member of Board of Directors since March 2021. Ms. Capps has also served as a member of the board of directors of Amedisys, Inc., a public healthcare company, since October 2019, and is the Chair of its audit committee and a member of its compensation committee. Ms. Capps has also served as a member of the board of directors of Orthofix Medical, Inc., a public medical technology company, since March 2025. In addition, Ms. Capps serves as a member of the boards of directors of Enable Injections, Inc. and Breg, Inc., both private medical device companies, a member of the senior advisory board of Consonance Capital Partners, a healthcare investment firm, and is also a member of the board of directors of the San Diego State University Research Foundation and a member of its audit committee and its finance and investment committee. Ms. Capps previously served on the board of directors of NuVasive, Inc., a public medical device company, from June 2015 until the closing of its merger with Globus Medical, Inc. in September 2023, of Otonomy, Inc., a public biotechnology company, from March 2014 until February 2023, of Silverback Therapeutics, Inc., a public biotechnology company, from June 2020 until the closing of its merger with ARS Pharmaceuticals, Inc. in November 2022, of Synthorx, Inc., a public biotechnology company, from April 2018 until its sale to Sanofi in January 2020, and of Connecture, Inc., a healthcare IT company, from October 2014 to April 2018. Ms. Capps has also previously served on the boards of directors of several other public and private companies, including OmniGuide Holdings, Inc., RF Surgical Systems, Inc., Eagle Rx, Inc. and SenoRx, Inc. From July 2002 to December 2013, Ms. Capps was the Chief Financial Officer of DJO Global, Inc., a medical device company. Prior to joining DJO Global, Inc., Ms. Capps served as the Chief Financial Officer of several other public and private companies. Earlier in her career, Ms. Capps was a senior audit and accounting professional at Ernst & Young LLP. Ms. Capps is a California Certified Public Accountant and was recognized as a CFO of the Year Honoree by the San Diego Business Journal in 2009 and 2010 and as a Director of the Year Honoree by the Corporate Directors Forum in 2022. Ms. Capps received a B.A. in Business Administration/Accounting from San Diego State University. - Vickie Capps自2021年3月起担任Janux Therapeutics, Inc.的董事会成员。Vickie Capps从2002年7月到2013年12月，担任DJO Global, Inc.的全球首席财务官。2002年她加入DJO Global, Inc.。加入DJO Global, Inc.之前，她担任其他公共和私人公司的首席财务官。在她的职业生涯的早期，她担任Ernst & Young LLP的高级审计和会计专业人才。她目前担任Consonance Capital Partners（医疗投资公司）的高级顾问委员会的成员并且是 RF Surgical Systems, Inc.的董事会成员以及其审计委员会主席。从2007年到2010年7月被C. R. Bard, Inc.收购之前，她担任SenoRx, Inc.的董事会的成员。她是加州注册会计师并且是被the San Diego Business Journal认证的2009年和2010年年度首席财务官。她获得San Diego State University的工商管理会计学士学位。
- Vickie Capps,has served as a member of Board of Directors since March 2021. Ms. Capps has also served as a member of the board of directors of Amedisys, Inc., a public healthcare company, since October 2019, and is the Chair of its audit committee and a member of its compensation committee. Ms. Capps has also served as a member of the board of directors of Orthofix Medical, Inc., a public medical technology company, since March 2025. In addition, Ms. Capps serves as a member of the boards of directors of Enable Injections, Inc. and Breg, Inc., both private medical device companies, a member of the senior advisory board of Consonance Capital Partners, a healthcare investment firm, and is also a member of the board of directors of the San Diego State University Research Foundation and a member of its audit committee and its finance and investment committee. Ms. Capps previously served on the board of directors of NuVasive, Inc., a public medical device company, from June 2015 until the closing of its merger with Globus Medical, Inc. in September 2023, of Otonomy, Inc., a public biotechnology company, from March 2014 until February 2023, of Silverback Therapeutics, Inc., a public biotechnology company, from June 2020 until the closing of its merger with ARS Pharmaceuticals, Inc. in November 2022, of Synthorx, Inc., a public biotechnology company, from April 2018 until its sale to Sanofi in January 2020, and of Connecture, Inc., a healthcare IT company, from October 2014 to April 2018. Ms. Capps has also previously served on the boards of directors of several other public and private companies, including OmniGuide Holdings, Inc., RF Surgical Systems, Inc., Eagle Rx, Inc. and SenoRx, Inc. From July 2002 to December 2013, Ms. Capps was the Chief Financial Officer of DJO Global, Inc., a medical device company. Prior to joining DJO Global, Inc., Ms. Capps served as the Chief Financial Officer of several other public and private companies. Earlier in her career, Ms. Capps was a senior audit and accounting professional at Ernst & Young LLP. Ms. Capps is a California Certified Public Accountant and was recognized as a CFO of the Year Honoree by the San Diego Business Journal in 2009 and 2010 and as a Director of the Year Honoree by the Corporate Directors Forum in 2022. Ms. Capps received a B.A. in Business Administration/Accounting from San Diego State University.
- Winston Kung
-
Winston Kung，2016年2月15日被任命为Pmv Pharmaceuticals, Inc.董事会成员。Kung先生是Celgene Corporation业务发展和全球联盟副总裁。2013年4月-2015年2月，他之前担任Celgene Corporation子公司Celgene Cellular Therapeutics业务总监。加入Celgene Cellular Therapeutics之前，2010年6月-2013年4月，Kung是花旗集团（citigroup）全球医疗保健企业和投资银行部门董事，他集中在生物技术和制药公司。2007年5月-2010年6月，他还在巴克莱前雷曼兄弟（Lehman Brothers）全球并购集团中担任副总裁。他的职业生涯在投资银行之前，Kung先生在Amgen和Genentech从事商业和企业开发团队。他拥有布朗大学生物学学士学位和哈佛商学院的工商管理硕士学位。
Winston Kung,has served as Arrivent Biopharma, Inc. Chief Financial Officer and Treasurer since January 2024. From December 2017 to January 2024, Mr. Kung served as Chief Operating Officer and Chief Financial Officer at PMV Pharmaceuticals (Nasdaq: PMVP), a precision oncology company. From April 2013 to November 2017, Mr. Kung worked at Celgene Corporation, a global biopharmaceutical company, where he held multiple positions, including Vice President of Business Development and Global Alliances, and Chief Business Officer at Celgene Cellular Therapeutics, Inc. (a wholly-owned subsidiary of Celgene Corporation). At Celgene, Mr. Kung led the formation of a strategic long-range plan for the company, along with overseeing multiple transactions and a team that managed the company's alliance portfolio of over 100 collaborations, equity investments and company integrations. Prior to working at Celgene, Mr. Kung worked at Citigroup Inc. from June 2010 to April 2013 in its Global Healthcare Investment Banking group and at Lehman Brothers (which was subsequently acquired by Barclays Capital Inc.) from May 2007 to June 2010 in its Global Mergers and Acquisitions Group. At Citigroup and Barclays, Mr. Kung worked on various transactions including public and private financings, mergers and acquisitions, spin-outs and other financial advisory engagements. From August 2004 to May 2007, Mr. Kung worked at Amgen Inc. (Nasdaq: AMGN), a global biopharmaceutical company, as a co-founder of the Alliance Management group, and served as the deal lead on multiple acquisitions as part of the Corporate Development group. Mr. Kung also worked at Genentech, Inc., a biotechnology company (acquired by Roche Group in March 2009), from November 1999 to September 2002 as part of the Business and Corporate Development group. Since September 2022, Mr. Kung has served on the oard of directors of Janux Therapeutics, Inc. (Nasdaq: JANX), a biopharmaceutical company. Mr. Kung previously served on the board of directors of Alliqua BioMedicial Inc. (Nasdaq: ALQA), a provider of advanced wound care products, and GNS Healthcare, Inc., a private, healthcare artificial intelligence company. Mr. Kung received a B.A. in Biology and International Relations from Brown University and a M.B.A. from Harvard Business School. - Winston Kung，2016年2月15日被任命为Pmv Pharmaceuticals, Inc.董事会成员。Kung先生是Celgene Corporation业务发展和全球联盟副总裁。2013年4月-2015年2月，他之前担任Celgene Corporation子公司Celgene Cellular Therapeutics业务总监。加入Celgene Cellular Therapeutics之前，2010年6月-2013年4月，Kung是花旗集团（citigroup）全球医疗保健企业和投资银行部门董事，他集中在生物技术和制药公司。2007年5月-2010年6月，他还在巴克莱前雷曼兄弟（Lehman Brothers）全球并购集团中担任副总裁。他的职业生涯在投资银行之前，Kung先生在Amgen和Genentech从事商业和企业开发团队。他拥有布朗大学生物学学士学位和哈佛商学院的工商管理硕士学位。
- Winston Kung,has served as Arrivent Biopharma, Inc. Chief Financial Officer and Treasurer since January 2024. From December 2017 to January 2024, Mr. Kung served as Chief Operating Officer and Chief Financial Officer at PMV Pharmaceuticals (Nasdaq: PMVP), a precision oncology company. From April 2013 to November 2017, Mr. Kung worked at Celgene Corporation, a global biopharmaceutical company, where he held multiple positions, including Vice President of Business Development and Global Alliances, and Chief Business Officer at Celgene Cellular Therapeutics, Inc. (a wholly-owned subsidiary of Celgene Corporation). At Celgene, Mr. Kung led the formation of a strategic long-range plan for the company, along with overseeing multiple transactions and a team that managed the company's alliance portfolio of over 100 collaborations, equity investments and company integrations. Prior to working at Celgene, Mr. Kung worked at Citigroup Inc. from June 2010 to April 2013 in its Global Healthcare Investment Banking group and at Lehman Brothers (which was subsequently acquired by Barclays Capital Inc.) from May 2007 to June 2010 in its Global Mergers and Acquisitions Group. At Citigroup and Barclays, Mr. Kung worked on various transactions including public and private financings, mergers and acquisitions, spin-outs and other financial advisory engagements. From August 2004 to May 2007, Mr. Kung worked at Amgen Inc. (Nasdaq: AMGN), a global biopharmaceutical company, as a co-founder of the Alliance Management group, and served as the deal lead on multiple acquisitions as part of the Corporate Development group. Mr. Kung also worked at Genentech, Inc., a biotechnology company (acquired by Roche Group in March 2009), from November 1999 to September 2002 as part of the Business and Corporate Development group. Since September 2022, Mr. Kung has served on the oard of directors of Janux Therapeutics, Inc. (Nasdaq: JANX), a biopharmaceutical company. Mr. Kung previously served on the board of directors of Alliqua BioMedicial Inc. (Nasdaq: ALQA), a provider of advanced wound care products, and GNS Healthcare, Inc., a private, healthcare artificial intelligence company. Mr. Kung received a B.A. in Biology and International Relations from Brown University and a M.B.A. from Harvard Business School.
- David Campbell
-
David Campbell是Janux Therapeutics, Inc.的创始人，自2017年6月成立以来一直担任总裁兼首席执行官。在成立Janux之前，2013年3月至2019年12月，Campbell博士在Avalon Ventures担任常驻企业家。2013年11月至2019年8月，Campbell博士担任Sitari Pharmaceuticals的首席科学官，2015年11月至2019年6月，Campbell博士担任Iron Horse Therapeutics的首席科学官从2015年11月到2017年12月，坎贝尔博士获得哈维穆德学院化学学士学位和博士学位。在康奈尔大学的有机化学专业，并在加利福尼亚大学、伯克利教授Peter Schultz博士的带领下接受博士后的培训。
David Campbell,is founder and has served as President and Chief Executive Officer and as a member of Board of Directors since inception in June 2017. Prior to founding Janux, Dr. Campbell was an Entrepreneur in Residence at Avalon Ventures from March 2013 to December 2019. Dr. Campbell served as the Chief Scientific Officer for Sitari Pharmaceuticals, Inc. from November 2013 through August 2019 and for Iron Horse Therapeutics, Inc. from November 2015 to June 2019. Dr. Campbell served as the President and Chief Executive Officer of Enlibirum from November 2015 through December 2017. Dr. Campbell received a B.S. in Chemistry from Harvey Mudd College and a Ph.D. in Organic Chemistry from Cornell University, and received post-doctoral training under then University of California, Berkeley professor Dr. Peter Schultz. - David Campbell是Janux Therapeutics, Inc.的创始人，自2017年6月成立以来一直担任总裁兼首席执行官。在成立Janux之前，2013年3月至2019年12月，Campbell博士在Avalon Ventures担任常驻企业家。2013年11月至2019年8月，Campbell博士担任Sitari Pharmaceuticals的首席科学官，2015年11月至2019年6月，Campbell博士担任Iron Horse Therapeutics的首席科学官从2015年11月到2017年12月，坎贝尔博士获得哈维穆德学院化学学士学位和博士学位。在康奈尔大学的有机化学专业，并在加利福尼亚大学、伯克利教授Peter Schultz博士的带领下接受博士后的培训。
- David Campbell,is founder and has served as President and Chief Executive Officer and as a member of Board of Directors since inception in June 2017. Prior to founding Janux, Dr. Campbell was an Entrepreneur in Residence at Avalon Ventures from March 2013 to December 2019. Dr. Campbell served as the Chief Scientific Officer for Sitari Pharmaceuticals, Inc. from November 2013 through August 2019 and for Iron Horse Therapeutics, Inc. from November 2015 to June 2019. Dr. Campbell served as the President and Chief Executive Officer of Enlibirum from November 2015 through December 2017. Dr. Campbell received a B.S. in Chemistry from Harvey Mudd College and a Ph.D. in Organic Chemistry from Cornell University, and received post-doctoral training under then University of California, Berkeley professor Dr. Peter Schultz.
- Jake Simson
-
Jake Simson，自2023年6月起担任Septerna，Inc.董事会成员。自2020年12月以来，Simson博士一直担任多阶段生命科学投资公司RA Capital的合伙人。2013年7月至2020年12月，Simson博士在RA Capital担任助理、分析师，随后担任负责人。Simson博士目前在上市的生物制药公司Bicara Therapeutics Inc.（纳斯达克：BCAX）的董事会、上市的免疫治疗公司Janux Therapeutics, Inc.（纳斯达克：JANX）和上市的精准医疗公司Tyra Biosciences, Inc.，Inc.（纳斯达克：TYRA）的董事会任职，还在多家私营生物技术公司的董事会任职。Simson博士此前曾在DICE Therapeutics, Inc.（纳斯达克：DICE）的董事会任职，DICE Therapeutics, Inc.是一家上市的生物制药公司，任职于2020年12月至2023年8月期间，DICE Therapeutics, Inc.被礼来公司收购。Simson博士在麻省理工学院获得材料科学与工程学士学位，在约翰斯·霍普金斯大学获得生物医学工程博士学位。
Jake Simson,has served as a member of Board of Directors since March 2021. Dr. Simson has served as a Partner at RA Capital Management, L.P. ("RA Capital") since December 2020. Previously, Dr. Simson served as an associate, analyst and principal at RA Capital from July 2013 to December 2020. Dr. Simson also serves as a member of the board of directors of Tyra Biosciences, a public biotechnology company, and each of Bicara Therapeutics, Convergent Therapeutics and Septerna, each a private biotechnology company. Dr. Simson received an S.B. in Materials Science and Engineering from the Massachusetts Institute of Technology and a Ph.D. in Biomedical Engineering from the Johns Hopkins University. - Jake Simson，自2023年6月起担任Septerna，Inc.董事会成员。自2020年12月以来，Simson博士一直担任多阶段生命科学投资公司RA Capital的合伙人。2013年7月至2020年12月，Simson博士在RA Capital担任助理、分析师，随后担任负责人。Simson博士目前在上市的生物制药公司Bicara Therapeutics Inc.（纳斯达克：BCAX）的董事会、上市的免疫治疗公司Janux Therapeutics, Inc.（纳斯达克：JANX）和上市的精准医疗公司Tyra Biosciences, Inc.，Inc.（纳斯达克：TYRA）的董事会任职，还在多家私营生物技术公司的董事会任职。Simson博士此前曾在DICE Therapeutics, Inc.（纳斯达克：DICE）的董事会任职，DICE Therapeutics, Inc.是一家上市的生物制药公司，任职于2020年12月至2023年8月期间，DICE Therapeutics, Inc.被礼来公司收购。Simson博士在麻省理工学院获得材料科学与工程学士学位，在约翰斯·霍普金斯大学获得生物医学工程博士学位。
- Jake Simson,has served as a member of Board of Directors since March 2021. Dr. Simson has served as a Partner at RA Capital Management, L.P. ("RA Capital") since December 2020. Previously, Dr. Simson served as an associate, analyst and principal at RA Capital from July 2013 to December 2020. Dr. Simson also serves as a member of the board of directors of Tyra Biosciences, a public biotechnology company, and each of Bicara Therapeutics, Convergent Therapeutics and Septerna, each a private biotechnology company. Dr. Simson received an S.B. in Materials Science and Engineering from the Massachusetts Institute of Technology and a Ph.D. in Biomedical Engineering from the Johns Hopkins University.
- Eric Dobmeier
-
Eric Dobmeier，自2022年12月起担任Structure Therapeutics公司董事会成员。Dobmeier先生自2019年4月起担任Chinook Therapeutics, Inc.（纳斯达克股票代码：KDNY）的总裁、首席执行官兼董事会成员，该公司是一家上市的生物技术公司，专注于肾脏疾病。在加入Chinook Therapeutics之前，Dobmeier先生于2018年1月至2018年6月担任Silverback Therapeutics，Inc.总裁兼首席执行官。在此之前，Dobmeier先生于2002年至2017年12月在生物技术上市公司Seattle Genetics, Inc.（纳斯达克股票代码：SGEN）担任越来越重要的职务，包括于2011年6月至2017年12月担任首席运营官。此前，Dobmeier先生是Venture Law Group和Heller Ehrman LLP律师事务所的一名律师，在那里他代表技术公司处理公共和私人融资、兼并和收购以及公司合伙交易。Dobmeier先生目前在Atara Biotherapeutics, Inc.（纳斯达克股票代码：ATRA）的董事会任职，该公司是一家上市的生物技术公司，自2015年起任职。Dobmeier先生此前曾于2016年至2021年在Adaptive Biotechnologies Corp（纳斯达克股票代码：ADPT）、2012年至2018年在Stemline Therapeutics, Inc.（纳斯达克股票代码：STML）以及2017年至2018年在Versartis的董事会任职，这两家公司都是一家上市的生物制药公司。他在普林斯顿大学获得历史学学士学位，在加州大学伯克利分校法学院获得法学博士学位。
Eric Dobmeier,has served as a member of Structure Therapeutics Inc. board of directors since December 2022. Since April 2019, Mr. Dobmeier has served as President, Chief Executive Officer and a member of the Board of Directors of Chinook Therapeutics, Inc. (NASDAQ: KDNY), a publicly traded biotechnology company focused on kidney diseases. Prior to joining Chinook Therapeutics, Mr. Dobmeier served as President and Chief Executive Officer of Silverback Therapeutics, Inc. from January 2018 to June 2018. Prior to that, Mr. Dobmeier held positions of increasing responsibility at Seattle Genetics, Inc. (NASDAQ: SGEN), a publicly traded biotechnology company, from 2002 to December 2017, including as Chief Operating Officer from June 2011 to December 2017. Previously, Mr. Dobmeier was an attorney with the law firms of Venture Law Group and Heller Ehrman LLP, where he represented technology companies in connection with public and private financings, mergers and acquisitions and corporate partnering transactions. Mr. Dobmeier currently serves on the board of directors of Atara Biotherapeutics, Inc. (NASDAQ: ATRA), a publicly traded biotechnology company, where he has served since 2015. Mr. Dobmeier previously served on the boards of directors of Adaptive Biotechnologies Corp (NASDAQ: ADPT) from 2016 to 2021, Stemline Therapeutics, Inc. (NASDAQ: STML) from 2012 to 2018 and Versartis from 2017 to 2018, each a publicly traded biopharmaceutical company. He received his A.B. in History from Princeton University and his J.D. from the University of California, Berkeley School of Law. - Eric Dobmeier，自2022年12月起担任Structure Therapeutics公司董事会成员。Dobmeier先生自2019年4月起担任Chinook Therapeutics, Inc.（纳斯达克股票代码：KDNY）的总裁、首席执行官兼董事会成员，该公司是一家上市的生物技术公司，专注于肾脏疾病。在加入Chinook Therapeutics之前，Dobmeier先生于2018年1月至2018年6月担任Silverback Therapeutics，Inc.总裁兼首席执行官。在此之前，Dobmeier先生于2002年至2017年12月在生物技术上市公司Seattle Genetics, Inc.（纳斯达克股票代码：SGEN）担任越来越重要的职务，包括于2011年6月至2017年12月担任首席运营官。此前，Dobmeier先生是Venture Law Group和Heller Ehrman LLP律师事务所的一名律师，在那里他代表技术公司处理公共和私人融资、兼并和收购以及公司合伙交易。Dobmeier先生目前在Atara Biotherapeutics, Inc.（纳斯达克股票代码：ATRA）的董事会任职，该公司是一家上市的生物技术公司，自2015年起任职。Dobmeier先生此前曾于2016年至2021年在Adaptive Biotechnologies Corp（纳斯达克股票代码：ADPT）、2012年至2018年在Stemline Therapeutics, Inc.（纳斯达克股票代码：STML）以及2017年至2018年在Versartis的董事会任职，这两家公司都是一家上市的生物制药公司。他在普林斯顿大学获得历史学学士学位，在加州大学伯克利分校法学院获得法学博士学位。
- Eric Dobmeier,has served as a member of Structure Therapeutics Inc. board of directors since December 2022. Since April 2019, Mr. Dobmeier has served as President, Chief Executive Officer and a member of the Board of Directors of Chinook Therapeutics, Inc. (NASDAQ: KDNY), a publicly traded biotechnology company focused on kidney diseases. Prior to joining Chinook Therapeutics, Mr. Dobmeier served as President and Chief Executive Officer of Silverback Therapeutics, Inc. from January 2018 to June 2018. Prior to that, Mr. Dobmeier held positions of increasing responsibility at Seattle Genetics, Inc. (NASDAQ: SGEN), a publicly traded biotechnology company, from 2002 to December 2017, including as Chief Operating Officer from June 2011 to December 2017. Previously, Mr. Dobmeier was an attorney with the law firms of Venture Law Group and Heller Ehrman LLP, where he represented technology companies in connection with public and private financings, mergers and acquisitions and corporate partnering transactions. Mr. Dobmeier currently serves on the board of directors of Atara Biotherapeutics, Inc. (NASDAQ: ATRA), a publicly traded biotechnology company, where he has served since 2015. Mr. Dobmeier previously served on the boards of directors of Adaptive Biotechnologies Corp (NASDAQ: ADPT) from 2016 to 2021, Stemline Therapeutics, Inc. (NASDAQ: STML) from 2012 to 2018 and Versartis from 2017 to 2018, each a publicly traded biopharmaceutical company. He received his A.B. in History from Princeton University and his J.D. from the University of California, Berkeley School of Law.
- Ron Barrett
-
Ron Barrett，自2021年9月起担任董事会成员。Barrett博士还担任民营肿瘤公司Quadriga Biosciences的董事会成员。Barrett博士于2023年1月至2023年7月担任生物制药公司Medikine，Inc.的执行董事长，此前曾于2017年6月至2023年1月担任其首席执行官和董事会主席，并于2016年12月至2017年6月担任其执行主席。Barrett博士是生物制药公司XenoPort生物制药，Inc.（“XenoPort生物制药”）的创始人，曾于2001年至2015年10月担任该公司的首席执行官，于1999年至2001年担任该公司的首席科学官，并于1999年至2015年10月担任该公司的董事会成员。在加入XenoPort生物制药之前，Barrett博士曾在Affymax Research Institute（一家药物发现公司，现在归葛兰素史克公司所有）和医疗保健公司（一家医疗保健公司）担任过多个职位。Barrett博士获得巴克内尔大学学士学位和罗格斯大学药理学博士学位。
Ron Barrett,has served as a member of Board of Directors since September 2021. Dr. Barrett also serves as a member of the board of directors of Quadriga Biosciences, a private oncology company. Dr. Barrett served as Executive Chairman of Medikine, Inc., a biopharmaceutical company, from January 2023 to July 2023 and previously served as its Chief Executive Officer and Chairman of the board of directors from June 2017 until January 2023, and as its Executive Chair from December 2016 to June 2017. Dr. Barrett was a founder of XenoPort, Inc. ("XenoPort"), a biopharmaceutical company, and served as its Chief Executive Officer from 2001 to October 2015, its Chief Scientific Officer from 1999 to 2001 and as a member of its board of directors from 1999 to October 2015. Prior to XenoPort, Dr. Barrett held various positions at Affymax Research Institute, a drug discovery company now owned by GlaxoSmithKline plc, and Abbott Laboratories, a healthcare company. Dr. Barrett received a B.S. from Bucknell University and a Ph.D. in Pharmacology from Rutgers University. - Ron Barrett，自2021年9月起担任董事会成员。Barrett博士还担任民营肿瘤公司Quadriga Biosciences的董事会成员。Barrett博士于2023年1月至2023年7月担任生物制药公司Medikine，Inc.的执行董事长，此前曾于2017年6月至2023年1月担任其首席执行官和董事会主席，并于2016年12月至2017年6月担任其执行主席。Barrett博士是生物制药公司XenoPort生物制药，Inc.（“XenoPort生物制药”）的创始人，曾于2001年至2015年10月担任该公司的首席执行官，于1999年至2001年担任该公司的首席科学官，并于1999年至2015年10月担任该公司的董事会成员。在加入XenoPort生物制药之前，Barrett博士曾在Affymax Research Institute（一家药物发现公司，现在归葛兰素史克公司所有）和医疗保健公司（一家医疗保健公司）担任过多个职位。Barrett博士获得巴克内尔大学学士学位和罗格斯大学药理学博士学位。
- Ron Barrett,has served as a member of Board of Directors since September 2021. Dr. Barrett also serves as a member of the board of directors of Quadriga Biosciences, a private oncology company. Dr. Barrett served as Executive Chairman of Medikine, Inc., a biopharmaceutical company, from January 2023 to July 2023 and previously served as its Chief Executive Officer and Chairman of the board of directors from June 2017 until January 2023, and as its Executive Chair from December 2016 to June 2017. Dr. Barrett was a founder of XenoPort, Inc. ("XenoPort"), a biopharmaceutical company, and served as its Chief Executive Officer from 2001 to October 2015, its Chief Scientific Officer from 1999 to 2001 and as a member of its board of directors from 1999 to October 2015. Prior to XenoPort, Dr. Barrett held various positions at Affymax Research Institute, a drug discovery company now owned by GlaxoSmithKline plc, and Abbott Laboratories, a healthcare company. Dr. Barrett received a B.S. from Bucknell University and a Ph.D. in Pharmacology from Rutgers University.
- Natasha Hernday
-
Natasha Hernday，自2024年7月起担任董事会成员。Hernday女士在业务发展、公司战略和联盟管理方面拥有丰富的经验，曾于2022年12月至2023年12月被辉瑞收购期间在Seagen Inc.（“Seagen”）担任首席商务官和执行委员会成员，此前曾于2020年10月至2022年12月担任企业发展执行副总裁。Hernday女士于2011年加入Seagen，在那里她建立并领导了负责许可交易、收购和战略联盟的业务开发团队。在加入Seagen之前，Hernday女士在安进工作了16年，在那里她开始了她的发现研究职业生涯，然后在企业发展和公司战略方面担任过多个领导职务，包括并购总监和对外合作总监，在众多高价值交易中发挥了关键作用。Hernday女士自2019年6月起担任Xoma Corp.董事会成员，自2024年9月起担任Firefly Biologics，Inc.董事会成员，并担任俄勒冈大学Knight Campus外部顾问委员会成员。Hernday女士此前曾在Alpine Immune Sciences, Inc.的董事会任职，任职时间自2020年12月至2024年5月被Vertex Pharmaceuticals Incorporated收购为止，并于2019年6月至2021年1月被PDL生物制药，Inc.收购。Hernday女士获得了加州大学圣巴巴拉分校的微生物学学士学位和佩珀代因大学的工商管理硕士学位。
Natasha Hernday,has served as a member of Board of Directors since July 2024. Ms. Hernday hass extensive experience in business development, corporate strategy and alliance management, having served as Chief Business Officer and a member of the Executive Committee at Seagen Inc. ("Seagen") from December 2022 until its acquisition by Pfizer in December 2023, and previously as Executive Vice President, Corporate Development from October 2020 until December 2022. Ms. Hernday joined Seagen in 2011 where she built and led the business development team responsible for licensing deals, acquisitions and strategic alliances. Prior to her role at Seagen, Ms. Hernday spent 16 years at Amgen, where she began her career in discovery research, then held various leadership positions in corporate development and corporate strategy, including as Director, Mergers & Acquisitions and as Director, Out-Partnering, playing a key role in numerous high-value transactions. Ms. Hernday has served on the boards of directors of Xoma Corp. since June 2019 and Firefly Biologics, Inc. since September 2024 and on the Knight Campus External Advisory Board for the University of Oregon. Ms. Hernday previously served on the boards of directors of Alpine Immune Sciences, Inc., from December 2020 until its acquisition by Vertex Pharmaceuticals Incorporated in May 2024, and PDL BioPharma, Inc., from June 2019 until January 2021. Ms. Hernday received a B.A. in microbiology from the University of California, Santa Barbara and an M.B.A. from Pepperdine University. - Natasha Hernday，自2024年7月起担任董事会成员。Hernday女士在业务发展、公司战略和联盟管理方面拥有丰富的经验，曾于2022年12月至2023年12月被辉瑞收购期间在Seagen Inc.（“Seagen”）担任首席商务官和执行委员会成员，此前曾于2020年10月至2022年12月担任企业发展执行副总裁。Hernday女士于2011年加入Seagen，在那里她建立并领导了负责许可交易、收购和战略联盟的业务开发团队。在加入Seagen之前，Hernday女士在安进工作了16年，在那里她开始了她的发现研究职业生涯，然后在企业发展和公司战略方面担任过多个领导职务，包括并购总监和对外合作总监，在众多高价值交易中发挥了关键作用。Hernday女士自2019年6月起担任Xoma Corp.董事会成员，自2024年9月起担任Firefly Biologics，Inc.董事会成员，并担任俄勒冈大学Knight Campus外部顾问委员会成员。Hernday女士此前曾在Alpine Immune Sciences, Inc.的董事会任职，任职时间自2020年12月至2024年5月被Vertex Pharmaceuticals Incorporated收购为止，并于2019年6月至2021年1月被PDL生物制药，Inc.收购。Hernday女士获得了加州大学圣巴巴拉分校的微生物学学士学位和佩珀代因大学的工商管理硕士学位。
- Natasha Hernday,has served as a member of Board of Directors since July 2024. Ms. Hernday hass extensive experience in business development, corporate strategy and alliance management, having served as Chief Business Officer and a member of the Executive Committee at Seagen Inc. ("Seagen") from December 2022 until its acquisition by Pfizer in December 2023, and previously as Executive Vice President, Corporate Development from October 2020 until December 2022. Ms. Hernday joined Seagen in 2011 where she built and led the business development team responsible for licensing deals, acquisitions and strategic alliances. Prior to her role at Seagen, Ms. Hernday spent 16 years at Amgen, where she began her career in discovery research, then held various leadership positions in corporate development and corporate strategy, including as Director, Mergers & Acquisitions and as Director, Out-Partnering, playing a key role in numerous high-value transactions. Ms. Hernday has served on the boards of directors of Xoma Corp. since June 2019 and Firefly Biologics, Inc. since September 2024 and on the Knight Campus External Advisory Board for the University of Oregon. Ms. Hernday previously served on the boards of directors of Alpine Immune Sciences, Inc., from December 2020 until its acquisition by Vertex Pharmaceuticals Incorporated in May 2024, and PDL BioPharma, Inc., from June 2019 until January 2021. Ms. Hernday received a B.A. in microbiology from the University of California, Santa Barbara and an M.B.A. from Pepperdine University.
- Alana McNulty
-
Alana McNulty，自2021年9月起担任董事会成员。McNulty女士于2019年7月至2022年7月期间担任eFFECTOR Therapeutics, Inc.（“Effector”）的首席商务官。此前，McNulty女士于2012年7月至2020年12月担任Effector的首席财务官（以咨询身份任职至2015年10月）。McNulty女士自2012年7月起至2014年11月被Shire plc收购之前担任旭光制药 Inc.的首席财务官，并自2011年3月起通过2011年11月被辉瑞 Inc.收购担任Excaliard Pharmaceuticals，Inc.的首席财务官。在此之前，McNulty女士于2004年至2011年担任BrainCells，Inc.的代理首席财务官，并于1998年至2003年担任Elitra Pharmaceuticals Inc.的首席财务官。在此之前，McNulty女士是Advanced Tissue Sciences的企业发展主管和业务部门总经理。McNulty女士自2023年2月起担任生物制药公司Lipidio Pharmaceuticals的董事会成员。McNulty女士获得了加州大学圣巴巴拉分校的生物学学士学位和加州大学洛杉矶分校安德森商学院的工商管理硕士学位。
Alana McNulty,has served as a member of Board of Directors since September 2021. Ms. McNulty served as Chief Business Officer of Effector Therapeutics, Inc. ("Effector") from July 2019 to July 2022. Previously, Ms. McNulty served as Chief Financial Officer of Effector from July 2012 until December 2020 (in a consulting capacity until October 2015). Ms. McNulty served as Chief Financial Officer of Lumena Pharmaceuticals Inc. from July 2012 until its acquisition by Shire plc in November 2014, and as Chief Financial Officer of Excaliard Pharmaceuticals, Inc. from March 2011 through its acquisition by Pfizer Inc. in November 2011. Prior to that, Ms. McNulty was acting Chief Financial Officer at BrainCells, Inc. from 2004 until 2011 and Chief Financial Officer of Elitra Pharmaceuticals Inc. from 1998 to 2003. Prior to that, Ms. McNulty was head of Corporate Development and a General Manager of a business unit at Advanced Tissue Sciences. Ms. McNulty has served on the board of directors of Lipidio Pharmaceuticals, a biopharmaceutical company, since February 2023. Ms. McNulty received a B.A. in Biology from the University of California, Santa Barbara and an M.B.A. from the Anderson School of Business at the University of California, Los Angeles. - Alana McNulty，自2021年9月起担任董事会成员。McNulty女士于2019年7月至2022年7月期间担任eFFECTOR Therapeutics, Inc.（“Effector”）的首席商务官。此前，McNulty女士于2012年7月至2020年12月担任Effector的首席财务官（以咨询身份任职至2015年10月）。McNulty女士自2012年7月起至2014年11月被Shire plc收购之前担任旭光制药 Inc.的首席财务官，并自2011年3月起通过2011年11月被辉瑞 Inc.收购担任Excaliard Pharmaceuticals，Inc.的首席财务官。在此之前，McNulty女士于2004年至2011年担任BrainCells，Inc.的代理首席财务官，并于1998年至2003年担任Elitra Pharmaceuticals Inc.的首席财务官。在此之前，McNulty女士是Advanced Tissue Sciences的企业发展主管和业务部门总经理。McNulty女士自2023年2月起担任生物制药公司Lipidio Pharmaceuticals的董事会成员。McNulty女士获得了加州大学圣巴巴拉分校的生物学学士学位和加州大学洛杉矶分校安德森商学院的工商管理硕士学位。
- Alana McNulty,has served as a member of Board of Directors since September 2021. Ms. McNulty served as Chief Business Officer of Effector Therapeutics, Inc. ("Effector") from July 2019 to July 2022. Previously, Ms. McNulty served as Chief Financial Officer of Effector from July 2012 until December 2020 (in a consulting capacity until October 2015). Ms. McNulty served as Chief Financial Officer of Lumena Pharmaceuticals Inc. from July 2012 until its acquisition by Shire plc in November 2014, and as Chief Financial Officer of Excaliard Pharmaceuticals, Inc. from March 2011 through its acquisition by Pfizer Inc. in November 2011. Prior to that, Ms. McNulty was acting Chief Financial Officer at BrainCells, Inc. from 2004 until 2011 and Chief Financial Officer of Elitra Pharmaceuticals Inc. from 1998 to 2003. Prior to that, Ms. McNulty was head of Corporate Development and a General Manager of a business unit at Advanced Tissue Sciences. Ms. McNulty has served on the board of directors of Lipidio Pharmaceuticals, a biopharmaceutical company, since February 2023. Ms. McNulty received a B.A. in Biology from the University of California, Santa Barbara and an M.B.A. from the Anderson School of Business at the University of California, Los Angeles.
- Sheila Gujrathi
-
Sheila Gujrathi自2021年3月起担任Janux Therapeutics, Inc.的董事会成员。Sheila Gujrathi， 医学博士。加入BMS之前，2002至2008年，她就职于Genentech，担任免疫学、组织生长及修复临床发展项目职位；1999至2002年，担任McKinsey & Company保健业务的管理顾问，为保健和制药业项目提供战略意见。她在西北大学（Northwestern University）获得生物医学工程学学士学位、医学教育加速荣誉项目医学博士学位。她在哈佛大学Brigham and Women’s Hospital完成了内科实习和住院医师实习，现在是内科注册医师。她在加利福尼亚大学旧金山分校（University of California, San Francisco）和斯坦福大学（Stanford University）变态反应与免疫学项目得到额外培训。
Sheila Gujrathi,has served as a member of Board of Directors since March 2021. Dr. Gujrathi also serves as the Chairperson of the board of directors of Immpact Bio, a biopharmaceutical company, and as the Executive Chair of the board of directors of Ventyx Biosciences, a public biopharmaceutical company. Dr. Gujrathi previously served as Chair of the board of directors of ADARx Pharmaceuticals, Inc., a biopharmaceutical company, from June 2020 to January 2025, and on the board of directors of Turning Point Therapeutics, Inc., a public biopharmaceutical company, from November 2017 to March 2021, and as Chair of the board of directors from April 2019 to March 2021. Dr. Gujrathi also previously served on the board of directors of Five Prime Therapeutics, Inc. (acquired by Amgen in April 2021) from December 2015 to June 2019 and Ambrx, Inc. from February 2014 until its acquisition in June 2015. Dr. Gujrathi is a Co-Founder of Gossamer Bio, Inc., a public biopharmaceutical company, and served as President and Chief Executive Officer from July 2018 to November 2020 and as President and Chief Operating Officer from October 2015 to June 2018 and as a member of its board of directors from October 2015 to November 2020. Previously, Dr. Gujrathi was the Chief Medical Officer of Receptos, Inc., a biopharmaceutical company, a position she held from June 2011 until its acquisition by Celgene Corporation in August 2015. Dr. Gujrathi joined Receptos, Inc. from Bristol-Myers Squibb Company ("Bristol-Meyers Squibb"), where she was Vice President of the Global Clinical Research Group in Immunology from 2008 until 2011. Prior to joining Bristol-Myers Squibb, Dr. Gujrathi worked at Genentech, Inc., where she held roles of increasing responsibility in the Immunology, Tissue Growth and Repair clinical development group from 2002 until 2008. From 1999 until 2002, Dr. Gujrathi was a management consultant at McKinsey & Company in the healthcare practice, where she provided strategic advice on a variety of projects in the healthcare and pharmaceutical industry. Dr. Gujrathi received her B.S. in Biomedical Engineering and an M.D. from Northwestern University in Medical Education. Dr. Gujrathi completed her internal medicine internship and residency at Brigham and Women's Hospital, Harvard Medical School and is board certified in internal medicine. Dr. Gujrathi received additional training at the University of California, San Francisco and Stanford University in their Allergy and Immunology Fellowship Program. - Sheila Gujrathi自2021年3月起担任Janux Therapeutics, Inc.的董事会成员。Sheila Gujrathi， 医学博士。加入BMS之前，2002至2008年，她就职于Genentech，担任免疫学、组织生长及修复临床发展项目职位；1999至2002年，担任McKinsey & Company保健业务的管理顾问，为保健和制药业项目提供战略意见。她在西北大学（Northwestern University）获得生物医学工程学学士学位、医学教育加速荣誉项目医学博士学位。她在哈佛大学Brigham and Women’s Hospital完成了内科实习和住院医师实习，现在是内科注册医师。她在加利福尼亚大学旧金山分校（University of California, San Francisco）和斯坦福大学（Stanford University）变态反应与免疫学项目得到额外培训。
- Sheila Gujrathi,has served as a member of Board of Directors since March 2021. Dr. Gujrathi also serves as the Chairperson of the board of directors of Immpact Bio, a biopharmaceutical company, and as the Executive Chair of the board of directors of Ventyx Biosciences, a public biopharmaceutical company. Dr. Gujrathi previously served as Chair of the board of directors of ADARx Pharmaceuticals, Inc., a biopharmaceutical company, from June 2020 to January 2025, and on the board of directors of Turning Point Therapeutics, Inc., a public biopharmaceutical company, from November 2017 to March 2021, and as Chair of the board of directors from April 2019 to March 2021. Dr. Gujrathi also previously served on the board of directors of Five Prime Therapeutics, Inc. (acquired by Amgen in April 2021) from December 2015 to June 2019 and Ambrx, Inc. from February 2014 until its acquisition in June 2015. Dr. Gujrathi is a Co-Founder of Gossamer Bio, Inc., a public biopharmaceutical company, and served as President and Chief Executive Officer from July 2018 to November 2020 and as President and Chief Operating Officer from October 2015 to June 2018 and as a member of its board of directors from October 2015 to November 2020. Previously, Dr. Gujrathi was the Chief Medical Officer of Receptos, Inc., a biopharmaceutical company, a position she held from June 2011 until its acquisition by Celgene Corporation in August 2015. Dr. Gujrathi joined Receptos, Inc. from Bristol-Myers Squibb Company ("Bristol-Meyers Squibb"), where she was Vice President of the Global Clinical Research Group in Immunology from 2008 until 2011. Prior to joining Bristol-Myers Squibb, Dr. Gujrathi worked at Genentech, Inc., where she held roles of increasing responsibility in the Immunology, Tissue Growth and Repair clinical development group from 2002 until 2008. From 1999 until 2002, Dr. Gujrathi was a management consultant at McKinsey & Company in the healthcare practice, where she provided strategic advice on a variety of projects in the healthcare and pharmaceutical industry. Dr. Gujrathi received her B.S. in Biomedical Engineering and an M.D. from Northwestern University in Medical Education. Dr. Gujrathi completed her internal medicine internship and residency at Brigham and Women's Hospital, Harvard Medical School and is board certified in internal medicine. Dr. Gujrathi received additional training at the University of California, San Francisco and Stanford University in their Allergy and Immunology Fellowship Program.
高管简历
中英对照 | 中文 | 英文- David Campbell
David Campbell是Janux Therapeutics, Inc.的创始人，自2017年6月成立以来一直担任总裁兼首席执行官。在成立Janux之前，2013年3月至2019年12月，Campbell博士在Avalon Ventures担任常驻企业家。2013年11月至2019年8月，Campbell博士担任Sitari Pharmaceuticals的首席科学官，2015年11月至2019年6月，Campbell博士担任Iron Horse Therapeutics的首席科学官从2015年11月到2017年12月，坎贝尔博士获得哈维穆德学院化学学士学位和博士学位。在康奈尔大学的有机化学专业，并在加利福尼亚大学、伯克利教授Peter Schultz博士的带领下接受博士后的培训。
David Campbell,is founder and has served as President and Chief Executive Officer and as a member of Board of Directors since inception in June 2017. Prior to founding Janux, Dr. Campbell was an Entrepreneur in Residence at Avalon Ventures from March 2013 to December 2019. Dr. Campbell served as the Chief Scientific Officer for Sitari Pharmaceuticals, Inc. from November 2013 through August 2019 and for Iron Horse Therapeutics, Inc. from November 2015 to June 2019. Dr. Campbell served as the President and Chief Executive Officer of Enlibirum from November 2015 through December 2017. Dr. Campbell received a B.S. in Chemistry from Harvey Mudd College and a Ph.D. in Organic Chemistry from Cornell University, and received post-doctoral training under then University of California, Berkeley professor Dr. Peter Schultz.- David Campbell是Janux Therapeutics, Inc.的创始人，自2017年6月成立以来一直担任总裁兼首席执行官。在成立Janux之前，2013年3月至2019年12月，Campbell博士在Avalon Ventures担任常驻企业家。2013年11月至2019年8月，Campbell博士担任Sitari Pharmaceuticals的首席科学官，2015年11月至2019年6月，Campbell博士担任Iron Horse Therapeutics的首席科学官从2015年11月到2017年12月，坎贝尔博士获得哈维穆德学院化学学士学位和博士学位。在康奈尔大学的有机化学专业，并在加利福尼亚大学、伯克利教授Peter Schultz博士的带领下接受博士后的培训。
- David Campbell,is founder and has served as President and Chief Executive Officer and as a member of Board of Directors since inception in June 2017. Prior to founding Janux, Dr. Campbell was an Entrepreneur in Residence at Avalon Ventures from March 2013 to December 2019. Dr. Campbell served as the Chief Scientific Officer for Sitari Pharmaceuticals, Inc. from November 2013 through August 2019 and for Iron Horse Therapeutics, Inc. from November 2015 to June 2019. Dr. Campbell served as the President and Chief Executive Officer of Enlibirum from November 2015 through December 2017. Dr. Campbell received a B.S. in Chemistry from Harvey Mudd College and a Ph.D. in Organic Chemistry from Cornell University, and received post-doctoral training under then University of California, Berkeley professor Dr. Peter Schultz.
- Andy Meyer
Andy Meyer自2021年3月起担任Janux Therapeutics, Inc.的首席业务官。此前，Meyer先生于2019年3月至2021年3月在Evercore担任生命科学投资银行团队的常务董事，并于2015年5月至2019年3月担任生命科学投资银行团队的副总裁。在Evercore之前，Meyer先生在美国银行美林担任了生命科学投资银行的副总裁，从2014年12月到2015年4月，从2011年7月到2014年12月成为生命科学投资银行团队的副总裁。Meyer先生在乔治城大学获得了BSBA的资助，并获得了来自USC Marshall的MBA学位。
Andy Meyer,has served as Chief Business Officer since March 2021. Previously, Mr. Meyer served at Evercore as a Managing Director on the Life Sciences Investment Banking team from March 2019 to March 2021 and as a Vice President on the Life Sciences Investment Banking team from May 2015 to March 2019. Prior to Evercore, Mr. Meyer served at Bank of America Merrill Lynch as a Vice President on the Life Sciences Investment Banking team from December 2014 through April 2015 and as an Associate on the Life Sciences Investment Banking team from July 2011 to December 2014. Mr. Meyer received a B.A. in Finance from Georgetown University and an MBA from the University of Southern California Marshall School of Business.- Andy Meyer自2021年3月起担任Janux Therapeutics, Inc.的首席业务官。此前，Meyer先生于2019年3月至2021年3月在Evercore担任生命科学投资银行团队的常务董事，并于2015年5月至2019年3月担任生命科学投资银行团队的副总裁。在Evercore之前，Meyer先生在美国银行美林担任了生命科学投资银行的副总裁，从2014年12月到2015年4月，从2011年7月到2014年12月成为生命科学投资银行团队的副总裁。Meyer先生在乔治城大学获得了BSBA的资助，并获得了来自USC Marshall的MBA学位。
- Andy Meyer,has served as Chief Business Officer since March 2021. Previously, Mr. Meyer served at Evercore as a Managing Director on the Life Sciences Investment Banking team from March 2019 to March 2021 and as a Vice President on the Life Sciences Investment Banking team from May 2015 to March 2019. Prior to Evercore, Mr. Meyer served at Bank of America Merrill Lynch as a Vice President on the Life Sciences Investment Banking team from December 2014 through April 2015 and as an Associate on the Life Sciences Investment Banking team from July 2011 to December 2014. Mr. Meyer received a B.A. in Finance from Georgetown University and an MBA from the University of Southern California Marshall School of Business.
- Thomas DiRaimondo
Thomas DiRaimondo是联合创始人之一，自2024年1月起担任首席科学官，此前曾于2023年1月至2023年12月担任执行董事、研发主管，于2022年1月至2022年12月担任Therapeutics Discovery高级总监，并于2018年1月至2021年12月担任研究总监。此前，DiRaimondo博士曾在他共同创立的Sitari Pharma，Inc.任职，自2020年1月起担任研究总监，自2013年12月起担任首席科学家。DiRaimondo博士在密歇根大学安娜堡分校获得化学工程学士学位和制药工程硕士学位，并在斯坦福大学获得化学工程硕士学位和博士学位。
Thomas DiRaimondo,is one of co-founders and has served as Chief Scientific Officer since January 2024 and had previously served as Executive Director, Head of Research and Development from January 2023 through December 2023, Senior Director of Therapeutics Discovery from January 2022 through December 2022, and Director of Research from January 2018 through December 2021. Previously, Dr. DiRaimondo served at Sitari Pharma, Inc., which he co-founded, as Director of Research from January 2020, and Principal Scientist from December 2013. Dr. DiRaimondo received a B.S.E in chemical engineering and M.Eng in pharmaceutical engineering from the University of Michigan, Ann Arbor as well as a M.S. and Ph.D. in chemical engineering from Stanford University.- Thomas DiRaimondo是联合创始人之一，自2024年1月起担任首席科学官，此前曾于2023年1月至2023年12月担任执行董事、研发主管，于2022年1月至2022年12月担任Therapeutics Discovery高级总监，并于2018年1月至2021年12月担任研究总监。此前，DiRaimondo博士曾在他共同创立的Sitari Pharma，Inc.任职，自2020年1月起担任研究总监，自2013年12月起担任首席科学家。DiRaimondo博士在密歇根大学安娜堡分校获得化学工程学士学位和制药工程硕士学位，并在斯坦福大学获得化学工程硕士学位和博士学位。
- Thomas DiRaimondo,is one of co-founders and has served as Chief Scientific Officer since January 2024 and had previously served as Executive Director, Head of Research and Development from January 2023 through December 2023, Senior Director of Therapeutics Discovery from January 2022 through December 2022, and Director of Research from January 2018 through December 2021. Previously, Dr. DiRaimondo served at Sitari Pharma, Inc., which he co-founded, as Director of Research from January 2020, and Principal Scientist from December 2013. Dr. DiRaimondo received a B.S.E in chemical engineering and M.Eng in pharmaceutical engineering from the University of Michigan, Ann Arbor as well as a M.S. and Ph.D. in chemical engineering from Stanford University.
- Zachariah McIver
Zachariah McIver，自2025年1月1日起担任首席医疗官，此前曾于2023年5月至2024年12月担任临床开发副总裁。此前，McIver博士于2018年至2023年4月在安进担任执行医学总监，在临床和相关研究策略的设计、实施和执行方面领导跨职能团队。从2013年到2018年，McIver博士在Wake Forest担任血液科/肿瘤科的主治医师。2011年至2013年，McIver博士担任杜兰大学医学院血液学/肿瘤学系的主治医师和研究调查员。McIver博士获得了俄勒冈大学的物理学和通识科学学士学位、俄亥俄大学整骨医学学院的医学博士学位（D.O.）以及维克森林大学医学院的分子医学和转化科学博士学位。他在克利夫兰诊所完成了内科住院医师实习，并在美国国立卫生研究院的国家心肺血液研究所完成了血液学和肿瘤学临床研究金。
Zachariah McIver,has served as Chief Medical Officer since January 1, 2025 and had previously served as Vice President, Clinical Development from May 2023 to December 2024. Previously, Dr. McIver served as Executive Medical Director at Amgen from 2018 to April 2023, leading cross-functional teams in the design, implementation, and execution of clinical and correlative study strategies. From 2013 to 2018, Dr. McIver served as an attending physician at Wake Forest in the hematology/oncology department. From 2011 to 2013, Dr. McIver served as an attending physician and a research investigator in the department of hematology/oncology at Tulane University School of Medicine. Dr. McIver received a B.S. in Physics and General Sciences from the University of Oregon, a Medical Doctorate (D.O.) from Ohio University College of Osteopathic Medicine and a Ph.D. in Molecular Medicine and Translational Sciences from Wake Forest University School of Medicine. He completed his internal medicine residency at the Cleveland Clinic, and his clinical fellowship in hematology and oncology at the National Heart, Lung, and Blood Institute at the National Institutes of Health.- Zachariah McIver，自2025年1月1日起担任首席医疗官，此前曾于2023年5月至2024年12月担任临床开发副总裁。此前，McIver博士于2018年至2023年4月在安进担任执行医学总监，在临床和相关研究策略的设计、实施和执行方面领导跨职能团队。从2013年到2018年，McIver博士在Wake Forest担任血液科/肿瘤科的主治医师。2011年至2013年，McIver博士担任杜兰大学医学院血液学/肿瘤学系的主治医师和研究调查员。McIver博士获得了俄勒冈大学的物理学和通识科学学士学位、俄亥俄大学整骨医学学院的医学博士学位（D.O.）以及维克森林大学医学院的分子医学和转化科学博士学位。他在克利夫兰诊所完成了内科住院医师实习，并在美国国立卫生研究院的国家心肺血液研究所完成了血液学和肿瘤学临床研究金。
- Zachariah McIver,has served as Chief Medical Officer since January 1, 2025 and had previously served as Vice President, Clinical Development from May 2023 to December 2024. Previously, Dr. McIver served as Executive Medical Director at Amgen from 2018 to April 2023, leading cross-functional teams in the design, implementation, and execution of clinical and correlative study strategies. From 2013 to 2018, Dr. McIver served as an attending physician at Wake Forest in the hematology/oncology department. From 2011 to 2013, Dr. McIver served as an attending physician and a research investigator in the department of hematology/oncology at Tulane University School of Medicine. Dr. McIver received a B.S. in Physics and General Sciences from the University of Oregon, a Medical Doctorate (D.O.) from Ohio University College of Osteopathic Medicine and a Ph.D. in Molecular Medicine and Translational Sciences from Wake Forest University School of Medicine. He completed his internal medicine residency at the Cleveland Clinic, and his clinical fellowship in hematology and oncology at the National Heart, Lung, and Blood Institute at the National Institutes of Health.
- Charles Winter
Charles Winter，自2023年1月起担任首席技术官，此前曾于2021年3月至2022年12月担任化学、制造和控制高级副总裁。此前，Winter先生曾于2020年8月至2021年3月在AnaptysBio担任化学、制造和控制副总裁，于2020年1月至2020年8月在赛诺菲担任化学、制造和控制副总裁，于2018年6月至2020年1月在SynthorxTERM2（于2020年1月被赛诺菲收购）担任化学、制造和控制副总裁，于2016年11月至2018年6月在Denali治疗担任生物制剂负责人，于JHL Biotech担任制造和技术副总裁，运营其cGMP合同制造工厂，于2015年7月至2016年8月，2011年9月至2015年6月在吉利德担任生物制剂开发总监，1994年至2011年9月在基因泰克担任，最近担任高级组长和首席工程师。温特先生获得了威斯康星大学麦迪逊分校化学工程学士学位。
Charles Winter,has served as Chief Technical Officer since January 2023 and had previously served as Senior Vice President of Chemistry, Manufacturing and Controls from March 2021 through December 2022. Previously, Mr. Winter served at AnaptysBio as Vice President of Chemistry, Manufacturing and Controls from August 2020 to March 2021, at Sanofi as Vice President of Chemistry, Manufacturing and Controls from January 2020 to August 2020, at Synthorx (acquired by Sanofi in January 2020) as Vice President of Chemistry, Manufacturing and Controls from June 2018 to January 2020, at Denali Therapeutics as Head of Biologics from November 2016 to June 2018, at JHL Biotech as Vice President of Manufacturing and Technology, running its cGMP contract manufacturing plant, from July 2015 to August 2016, at Gilead as Director of Biologics Development from September 2011 to June 2015 and at Genentech from 1994 to September 2011, most recently as Senior Group Leader and Principal Engineer. Mr. Winter received a B.S. in chemical engineering from the University of Wisconsin-Madison.- Charles Winter，自2023年1月起担任首席技术官，此前曾于2021年3月至2022年12月担任化学、制造和控制高级副总裁。此前，Winter先生曾于2020年8月至2021年3月在AnaptysBio担任化学、制造和控制副总裁，于2020年1月至2020年8月在赛诺菲担任化学、制造和控制副总裁，于2018年6月至2020年1月在SynthorxTERM2（于2020年1月被赛诺菲收购）担任化学、制造和控制副总裁，于2016年11月至2018年6月在Denali治疗担任生物制剂负责人，于JHL Biotech担任制造和技术副总裁，运营其cGMP合同制造工厂，于2015年7月至2016年8月，2011年9月至2015年6月在吉利德担任生物制剂开发总监，1994年至2011年9月在基因泰克担任，最近担任高级组长和首席工程师。温特先生获得了威斯康星大学麦迪逊分校化学工程学士学位。
- Charles Winter,has served as Chief Technical Officer since January 2023 and had previously served as Senior Vice President of Chemistry, Manufacturing and Controls from March 2021 through December 2022. Previously, Mr. Winter served at AnaptysBio as Vice President of Chemistry, Manufacturing and Controls from August 2020 to March 2021, at Sanofi as Vice President of Chemistry, Manufacturing and Controls from January 2020 to August 2020, at Synthorx (acquired by Sanofi in January 2020) as Vice President of Chemistry, Manufacturing and Controls from June 2018 to January 2020, at Denali Therapeutics as Head of Biologics from November 2016 to June 2018, at JHL Biotech as Vice President of Manufacturing and Technology, running its cGMP contract manufacturing plant, from July 2015 to August 2016, at Gilead as Director of Biologics Development from September 2011 to June 2015 and at Genentech from 1994 to September 2011, most recently as Senior Group Leader and Principal Engineer. Mr. Winter received a B.S. in chemical engineering from the University of Wisconsin-Madison.